Pfizer Inc. (JOBS) Seeks Sutent OK for Pancreatic Cancer

Bookmark and Share

Reuters -- Pfizer Inc (PFE.N) said on Friday it has asked U.S., European and Canadian regulators for permission to market its already approved medicine Sutent as a treatment for patients with a rare type of pancreatic cancer. Pfizer said it had sought approval to market the pill for advanced pancreatic neuroendocrine tumors, the type of pancreatic cancer that has afflicted Apple Inc (AAPL.O) Chief Executive Steve Jobs.

Back to news